CY1123518T1 - Ανθρωπινα αντισωματα enanti-tau - Google Patents
Ανθρωπινα αντισωματα enanti-tauInfo
- Publication number
- CY1123518T1 CY1123518T1 CY20201100854T CY201100854T CY1123518T1 CY 1123518 T1 CY1123518 T1 CY 1123518T1 CY 20201100854 T CY20201100854 T CY 20201100854T CY 201100854 T CY201100854 T CY 201100854T CY 1123518 T1 CY1123518 T1 CY 1123518T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tau
- well
- enanti
- human
- tau antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Abstract
Παρέχονται νέα ανθρώπινα tau-ειδικά αντισώματα όπως επίσης θραύσματα, παράγωγα και παραλλαγές αυτών όπως επίσης μέθοδοι σχετικές με αυτά. Αποκαλύπτονται επίσης προσδιορισμοί, κιτ και στερεοί φορείς που σχετίζονται με αντισώματα ειδικά για tau. To αντίσωμα, αλυσίδα(ες) ανοσοσφαιρίνης, όπως επίσης θραύσματα δέσμευσης, παράγωγα και παραλλαγές αυτών μπορούν να χρησιμοποιηθούν σε φαρμακευτικές και διαγνωστικές συνθέσεις για tau στοχευμένη ανοσοθεραπεία και διάγνωση, αντίστοιχα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745410P | 2012-12-21 | 2012-12-21 | |
PCT/US2013/076952 WO2014100600A2 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123518T1 true CY1123518T1 (el) | 2022-03-24 |
Family
ID=49920689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100854T CY1123518T1 (el) | 2012-12-21 | 2020-09-09 | Ανθρωπινα αντισωματα enanti-tau |
Country Status (26)
Country | Link |
---|---|
US (4) | US9598484B2 (el) |
EP (2) | EP3792278A3 (el) |
JP (1) | JP6284548B2 (el) |
KR (1) | KR102234324B1 (el) |
CN (2) | CN111205368B (el) |
AU (1) | AU2013361107B2 (el) |
BR (1) | BR112015014751A8 (el) |
CA (1) | CA2896066C (el) |
CY (1) | CY1123518T1 (el) |
DK (1) | DK2935326T3 (el) |
EA (1) | EA035932B1 (el) |
ES (1) | ES2816700T3 (el) |
HK (1) | HK1216538A1 (el) |
HR (1) | HRP20201422T1 (el) |
HU (1) | HUE051320T2 (el) |
IL (1) | IL239556B (el) |
LT (1) | LT2935326T (el) |
MX (1) | MX2015008024A (el) |
MY (1) | MY184251A (el) |
PH (2) | PH12015501420B1 (el) |
PT (1) | PT2935326T (el) |
RS (1) | RS60899B1 (el) |
SG (2) | SG10201705104UA (el) |
SI (1) | SI2935326T1 (el) |
WO (1) | WO2014100600A2 (el) |
ZA (1) | ZA201504898B (el) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014503178A (ja) | 2010-10-11 | 2014-02-13 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗タウ抗体 |
CN104781278B (zh) | 2012-07-03 | 2018-06-12 | 华盛顿大学 | 针对tau的抗体 |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
CN107074935B (zh) | 2014-06-26 | 2021-08-03 | 扬森疫苗与预防公司 | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
DE102014013571A1 (de) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
EP3786182A1 (en) | 2014-11-19 | 2021-03-03 | Axon Neuroscience SE | Humanized tau antibodies in alzheimer's disease |
WO2016137950A1 (en) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
AR103713A1 (es) * | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
CN107849124B (zh) | 2015-06-05 | 2021-09-24 | 基因泰克公司 | 抗tau抗体及使用方法 |
US10287343B2 (en) | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
MA41669A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
PL3430397T3 (pl) | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
KR102471787B1 (ko) * | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
CN109415434B (zh) * | 2016-05-02 | 2022-12-30 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
IL263433B2 (en) | 2016-06-07 | 2024-03-01 | Biogen Int Neuroscience Gmbh | Methods for treating Alzheimer's disease |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
AU2017373884A1 (en) * | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
CR20230163A (es) | 2016-12-07 | 2023-07-06 | Genentech Inc | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) |
EP3562840A1 (en) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
US11249093B2 (en) * | 2017-03-28 | 2022-02-15 | Janssen Vaccines & Prevention B.V. | Methods for detection of Tau protein aggregation modulating compounds |
TW202400231A (zh) | 2017-03-28 | 2024-01-01 | 美商建南德克公司 | 治療神經退化性疾病之方法 |
CA3061516A1 (en) * | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
TWI750419B (zh) | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
US11629183B2 (en) | 2017-12-29 | 2023-04-18 | University Of Florida Research Foundation, Inc. | Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo |
WO2019171258A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
CN111918875A (zh) * | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
CA3111907A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
MA54070A (fr) | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
AU2019377595A1 (en) * | 2018-11-08 | 2021-05-27 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2020252394A2 (en) * | 2019-06-13 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia |
KR20220050127A (ko) * | 2019-07-23 | 2022-04-22 | 상하이테크 유니버시티 | Asic1 채널 안타고니스트 항체 |
TWI780464B (zh) | 2019-08-06 | 2022-10-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
EP4049839A4 (en) | 2019-10-25 | 2023-11-29 | Toyobo Co., Ltd. | LASER PRINTABLE FILM AND PACKAGING IN WHICH IT IS USED |
AR122721A1 (es) | 2020-06-25 | 2022-09-28 | Merck Sharp & Dohme | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 |
GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
AU2021403010A1 (en) * | 2020-12-16 | 2023-07-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
JP3909084B2 (ja) * | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
US5843779A (en) | 1992-12-14 | 1998-12-01 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies |
EP0737208B1 (en) | 1993-12-21 | 2006-08-02 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
AU710952B2 (en) | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
WO2002060955A2 (en) | 2001-01-29 | 2002-08-08 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
JP2004538324A (ja) | 2001-08-03 | 2004-12-24 | メディカル リサーチ カウンシル | 細胞内抗体 |
EP1418807B8 (en) | 2001-08-24 | 2008-04-23 | Universität Zürich | A method of inducing the formation of neurofibrillary tangles in transgenic animals |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
EP1535930B1 (en) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Antibody specific to central nervous system tau protein |
AU2003276107A1 (en) | 2003-04-24 | 2004-11-19 | Universitat Zurich | Method of monitoring immunotherapy |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
CN103408661B (zh) | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
CA2722082C (en) * | 2008-04-25 | 2021-11-09 | Christopher Tenhoor | Fc receptor binding proteins |
CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
TW201216985A (en) | 2010-10-07 | 2012-05-01 | Ac Immune Sa | Pharmaceutical composition |
JP2014503178A (ja) | 2010-10-11 | 2014-02-13 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗タウ抗体 |
US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
-
2013
- 2013-12-20 EA EA201591020A patent/EA035932B1/ru unknown
- 2013-12-20 HU HUE13818637A patent/HUE051320T2/hu unknown
- 2013-12-20 AU AU2013361107A patent/AU2013361107B2/en active Active
- 2013-12-20 CA CA2896066A patent/CA2896066C/en active Active
- 2013-12-20 EP EP20178431.1A patent/EP3792278A3/en not_active Withdrawn
- 2013-12-20 EP EP13818637.4A patent/EP2935326B1/en active Active
- 2013-12-20 DK DK13818637.4T patent/DK2935326T3/da active
- 2013-12-20 WO PCT/US2013/076952 patent/WO2014100600A2/en active Application Filing
- 2013-12-20 SG SG10201705104UA patent/SG10201705104UA/en unknown
- 2013-12-20 MX MX2015008024A patent/MX2015008024A/es active IP Right Grant
- 2013-12-20 SI SI201331780T patent/SI2935326T1/sl unknown
- 2013-12-20 SG SG11201504822VA patent/SG11201504822VA/en unknown
- 2013-12-20 JP JP2015549784A patent/JP6284548B2/ja active Active
- 2013-12-20 KR KR1020157019330A patent/KR102234324B1/ko active IP Right Grant
- 2013-12-20 LT LTEP13818637.4T patent/LT2935326T/lt unknown
- 2013-12-20 PT PT138186374T patent/PT2935326T/pt unknown
- 2013-12-20 RS RS20201060A patent/RS60899B1/sr unknown
- 2013-12-20 CN CN201911004609.5A patent/CN111205368B/zh active Active
- 2013-12-20 MY MYPI2015001581A patent/MY184251A/en unknown
- 2013-12-20 CN CN201380073531.7A patent/CN105324394B/zh active Active
- 2013-12-20 ES ES13818637T patent/ES2816700T3/es active Active
- 2013-12-20 US US14/654,176 patent/US9598484B2/en active Active
- 2013-12-20 BR BR112015014751A patent/BR112015014751A8/pt not_active Application Discontinuation
-
2015
- 2015-06-19 PH PH12015501420A patent/PH12015501420B1/en unknown
- 2015-06-21 IL IL239556A patent/IL239556B/en active IP Right Grant
- 2015-07-08 ZA ZA201504898A patent/ZA201504898B/en unknown
-
2016
- 2016-04-19 HK HK16104461.4A patent/HK1216538A1/zh unknown
-
2017
- 2017-02-08 US US15/427,843 patent/US20170369560A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,346 patent/US20190169274A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,152 patent/US20200262895A1/en not_active Abandoned
-
2020
- 2020-09-07 HR HRP20201422TT patent/HRP20201422T1/hr unknown
- 2020-09-09 CY CY20201100854T patent/CY1123518T1/el unknown
-
2021
- 2021-01-13 PH PH12021550083A patent/PH12021550083A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CY1121536T1 (el) | Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης | |
CY1122210T1 (el) | Ανθρωπινα αντισωματα anti-sod1 | |
CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
MX2018008680A (es) | Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43). | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
EA201500502A1 (ru) | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 | |
CY1120686T1 (el) | Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων | |
AR124605A2 (es) | Anticuerpos anti-il-36r | |
MX360580B (es) | Autoanticuerpos humanos anti-alfa-sinucleina. |